Albireo to Present at Wedbush PacGrow Healthcare Conference
August 06 2019 - 8:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that Ron Cooper, President and
Chief Executive Officer, will present at the Wedbush PacGrow
Healthcare Conference in New York City on Tuesday, August 13, 2019,
at 8:35 a.m. EDT.
A live audio webcast of the presentation will be accessible from
the Media & Investors page of Albireo’s
website, ir.albireopharma.com. To ensure a timely connection
to the webcast, it is recommended that users register at least 15
minutes prior to the scheduled start time. An archived version of
the webcast will be available for replay in the Events &
Presentations section of the Media & Investors page of
Albireo’s website for at least two weeks following the event.
About AlbireoAlbireo Pharma is a
clinical-stage biopharmaceutical company focused through its
operating subsidiary on the development of novel bile acid
modulators to treat orphan pediatric liver diseases, and other
liver and gastrointestinal diseases and disorders. Albireo’s lead
product candidate, odevixibat (A4250), is being developed to treat
rare pediatric cholestatic liver diseases and is in Phase 3
development in its initial target indication, progressive familial
intrahepatic cholestasis. Albireo’s clinical pipeline also includes
two Phase 2 product candidates. Elobixibat is in Phase 2
development in NAFLD and NASH. Approved in Japan for the
treatment of chronic constipation, elobixibat is the
first ileal bile acid transporter (IBAT) inhibitor approved
anywhere in the world.
Albireo was spun out from AstraZeneca in
2008. Albireo is located in Boston, Mass., and its key
operating subsidiary is located in Gothenburg, Sweden.
The Boston Business Journal named Albireo one of the 2019
Best Places to Work in Massachusetts. For more information on
Albireo, please
visit www.albireopharma.com.
Investor Contact: Hans Vitzthum, LifeSci
Advisors, LLC,
212-915-2568
Media Contact: Heather Anderson, 6 Degrees,
980-938-0260, handerson@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024